Skip to content


Sylvant (siltuximab) is an antibody pharmaceutical. Siltuximab was first approved as Sylvant on 2014-04-23. It is used to treat castleman disease in the USA. It has been approved in Europe to treat focal nodular hyperplasia. The pharmaceutical is active against interleukin-6.
Trade Name Sylvant
Common Name Siltuximab
Indication castleman disease, focal nodular hyperplasia
Drug Class Monoclonal antibodies: chimeric, tumors as target
Get full access now